386 related articles for article (PubMed ID: 1868454)
1. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
Griffin T; Raso V
Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma.
Griffin TW; Richardson C; Houston LL; LePage D; Bogden A; Raso V
Cancer Res; 1987 Aug; 47(16):4266-70. PubMed ID: 3496960
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of antitumor immunotoxins by liposomal monensin.
Griffin T; Rybak ME; Recht L; Singh M; Salimi A; Raso V
J Natl Cancer Inst; 1993 Feb; 85(4):292-8. PubMed ID: 8426373
[TBL] [Abstract][Full Text] [Related]
4. In vitro cytotoxicity of recombinant ricin A chain-antitransferrin receptor immunotoxin against human adenocarcinomas of the colon and pancreas.
Griffin TW; Pagnini PG; McGrath JJ; McCann JC; Houston LL
J Biol Response Mod; 1988 Dec; 7(6):559-67. PubMed ID: 3265147
[TBL] [Abstract][Full Text] [Related]
5. Improved pharmacokinetics and tumor localization of immunotoxins constructed with the Mr 30,000 form of ricin A chain.
Trown PW; Reardan DT; Carroll SF; Stoudemire JB; Kawahata RT
Cancer Res; 1991 Aug; 51(16):4219-25. PubMed ID: 1868442
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of the cytotoxic effect of anti-carcinoembryonic antigen immunotoxins by adenovirus and carboxylic ionophores.
Griffin TW; Childs LR; FitzGerald DJ; Levin LV
J Natl Cancer Inst; 1987 Oct; 79(4):679-85. PubMed ID: 3498854
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human tumor growth by intraperitoneal immunotoxins in nude mice.
Marks A; Ettenson D; Bjorn MJ; Lei M; Baumal R
Cancer Res; 1990 Jan; 50(2):288-92. PubMed ID: 2295069
[TBL] [Abstract][Full Text] [Related]
8. Carrier protein-monensin conjugates: enhancement of immunotoxin cytotoxicity and potential in tumor treatment.
Colombatti M; Dell'Arciprete L; Chignola R; Tridente G
Cancer Res; 1990 Mar; 50(5):1385-91. PubMed ID: 2302703
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
11. Potent cytotoxicity of an antihuman transferrin receptor-ricin A-chain immunotoxin on human glioma cells in vitro.
Recht LD; Griffin TW; Raso V; Salimi AR
Cancer Res; 1990 Oct; 50(20):6696-700. PubMed ID: 2208135
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo enhancement of ricin-A chain immunotoxin activity by novel indolizine calcium channel blockers: delayed intracellular degradation linked to lipidosis induction.
Jaffrézou JP; Levade T; Thurneyssen O; Chiron M; Bordier C; Attal M; Chatelain P; Laurent G
Cancer Res; 1992 Mar; 52(5):1352-9. PubMed ID: 1737397
[TBL] [Abstract][Full Text] [Related]
13. Preclinical assessments of 90Y-labeled C110 anti-carcinoembryonic antigen immunotoxin: a therapeutic immunoconjugate for human colon cancer.
Ito T; Qiu H; Collins JA; Brill AB; Johnson DK; Griffin TW
Cancer Res; 1991 Jan; 51(1):255-60. PubMed ID: 1988087
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J
Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of the specific cytotoxicity of a breast cancer-associated antigen immunotoxin by the carboxylic ionophore monensin.
Griffin TW; Pagnini PG; Houston LL
J Biol Response Mod; 1987 Oct; 6(5):537-45. PubMed ID: 3500277
[TBL] [Abstract][Full Text] [Related]
16. Blocking effect of human serum but not of cerebrospinal fluid on ricin A chain immunotoxin potentiation by monensin or carrier protein-monensin conjugates.
Candiani C; Franceschi A; Chignola R; Pasti M; Anselmi C; Benoni G; Tridente G; Colombatti M
Cancer Res; 1992 Feb; 52(3):623-30. PubMed ID: 1732050
[TBL] [Abstract][Full Text] [Related]
17. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds.
Ramakrishnan S; Bjorn MJ; Houston LL
Cancer Res; 1989 Feb; 49(3):613-7. PubMed ID: 2783383
[TBL] [Abstract][Full Text] [Related]
18. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
Ettenson D; Sheldon K; Marks A; Houston LL; Baumal R
Anticancer Res; 1988; 8(4):833-8. PubMed ID: 3263079
[TBL] [Abstract][Full Text] [Related]
19. Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant alpha-interferon and daunorubicin.
Yokota S; Hara H; Luo Y; Seon BK
Cancer Res; 1990 Jan; 50(1):32-7. PubMed ID: 2293557
[TBL] [Abstract][Full Text] [Related]
20. Mediation of reduction of spontaneous and experimental pulmonary metastases by ricin A-chain immunotoxin 45-2D9-RTA with potentiation by systemic monensin in mice.
Roth JA; Ames RS; Fry K; Lee HM; Scannon PJ
Cancer Res; 1988 Jun; 48(12):3496-501. PubMed ID: 3259469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
